A History of Prenatal and Genetic Screening Innovation

NTD Eurofins – A History of Innovation

Since its inception, NTD Eurofins has demonstrated a history of innovation, beginning with its work in neural tube defect research and continuing to where it stands today, at the forefront of prenatal care and genetic screening.

NTD Eurofins was the first to introduce;

ONTD Screening
Down Syndrome Screening
First Trimester Screening
Early Onset Preeclampsia Screening

Today, NTD Eurofins provides first and second trimester prenatal screening, genetic carrier screening, and hereditary cancer screening services to universities, medical centers, hospitals, laboratories, obstetricians and maternal fetal medicine (MFM) specialists worldwide through an accredited facility owned and operated by Eurofins Scientific. With an unwavering commitment to quality, combined with industry-leading best practices, NTD Eurofins remains at the forefront of research and innovation in maternal fetal healthcare industry.

Over Three Decades of Prenatal Screening

NTD Timeline

1976
AFP

First AFP screening for neural tube defects introduced in the United States of America by James N. Macri.
1983
NTD Labs Founded

NTD Labs was incorporated by Dr. Macri as a prenatal screening and research laboratory.
1989
Free Beta hCG

Discovered free beta hCG as the most discriminatory biochemical marker for Down syndrome.
1995
First Trimester Screen | Fß

NTD introduces first trimester Down syndrome screening.
2003
Landmark NICHD Study

Large multi-center study published in the New England Journal of Medicine validates the advantages of the free Beta hCG/PAPP-A/NT protocol.
2005
Nasal Bone Assessment

Fetal nasal bone assessment protocol introduced as part of NTD Labs first trimester Down syndrome screening protocol.
2007
Instant Risk Assessment

NTD introduces web portal to facilitate Instant Risk Assessment reporting within the Down syndrome screening protocol.
2013
Early Onset Preeclampsia Screen

NTD introduces the first serum screening test for early onset preeclampsia in the U.S.
2013
NIPT

NTD offers verifi cell free DNA screening through Illumina, Inc.
2015
AFP in First Trimester

NTD enhances it’s screening protocol with the addition of alpha fetoprotein (AFP) in the first trimester to improve the detection rate of Down syndrome. Learn more.
2016
Eurofins NTD Acquisition

NTD is acquired by Eurofins Scientific. Learn more.
2017
Maternal Fetal Screen^SM | T1

NTD launches Maternal Fetal Screen^SM | T1, offering both T21, 18/13 and early onset preeclampsia risk assessment results on one patient report. Learn more.
2018
NTD Offers Genetic Testing

NTD joins with sister laboratory, EGL Genetics, to offer genetic carrier and hereditary cancer screening services.